NCT03444714View on ClinicalTrials.gov

Phase I Study of RiMO-301 With Radiation in Advanced Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 10, 2018

Primary Completion Date

June 16, 2025

Study Completion Date

June 16, 2025

Conditions
Advanced Tumors
Interventions
DRUG

RiMO-301

"Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection~Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks"

Trial Locations (2)

60612

University of Illinois at Chicago, Chicago

60637

University of Chicago Medical Center, Chicago

Sponsors
All Listed Sponsors
collaborator

University of Chicago

OTHER

lead

Coordination Pharmaceuticals, Inc.

INDUSTRY